# Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors

> **NCT03585465** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Oscar Lambret** · enrollment: 63 (actual)

## Conditions studied

- Childhood Solid Tumor

## Interventions

- **DRUG:** Vinblastine
- **DRUG:** Cyclophosphamide
- **DRUG:** Capecitabine
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03585465
- **Lead sponsor:** Centre Oscar Lambret
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-26
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-01
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03585465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03585465, "Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03585465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*